Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023


Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2023 financial results on Thursday, November 2nd, 2023. Mirum will also host a conference call to discuss the third quarter 2023 financial results and recent corporate progress.

Conference call details:
Thursday, November 2nd, 2023
4:30 p.m. ET / 1:30 p.m. PT

Dial-in:
U.S./Toll-Free: +1 833 470 1428
International: +1 404 975 4839
Passcode: 979561

You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid) capsules, and Chenodal® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in Canada. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older. Cholbam is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. Chenodal has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum's late-stage pipeline includes three investigational treatments for debilitating liver diseases. The LIVMARLI development program includes the Phase 2b EMBARK study for biliary atresia. Mirum's second investigational IBAT inhibitor is volixibat, which is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, Chenodal, is being evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter.


These press releases may also interest you

at 20:07
Ascentage Pharma Received US$100 Million Option Payment from Takeda
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

at 18:46
BOXABL Investors Have Now Indicated They Want to Invest Over $10MM in the Current Stock Offering! BOXABL Previously Sold Out the Reg A Crowdfund
BOXABL, the innovative housing startup known for its foldable Casita homes and building technology, has announced this week that investors have indicated they want to invest over $10MM in the current stock offering. BOXABL previously SOLD OUT the Reg...

at 18:18
PATH Investors Have Opportunity to Lead UiPath Inc. Securities Fraud Lawsuit
Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against UiPath Inc. ("UiPath" or the "Company") . Class Period: December 1, 2023 ? May 29, 2024 Lead...

at 18:15
Payfare Announces Completion of 2023 Annual Filings
Payfare Inc. ("Payfare" or the "Company")  today announces the completion of the filing of its audited annual financial statements, management's discussion and analysis, annual information form and related certifications, all for the year ended...

at 17:53
Partnership announcement between the Mohanji Foundation USA, World Consciousness Alliance, and The Diplomatic Club to promote Spiritual and Cultural Diplomacy Globally
The Mohanji Foundation, a global non-profit organization founded by Mohanji; World Consciousness Alliance, a Mohanji-founded platform for artists dedicated to raising awareness; and The Diplomatic Club, a non-political, non-profit organization...

at 17:45
Online Home Rental Services Market size is set to grow by USD 28.01 billion from 2024-2028, High real estate prices make homeownership unaffordable boost the market, Technavio
The global online home rental services market size is estimated to grow by USD 28.01 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 14.72% during the forecast period. High real estate prices make...

More news about Business...


News published on and distributed by: